NALOXEGOL (naloxegol) by Msn Labs Pvt Ltd is mu-opioid receptor. Approved for opioid-induced constipation (oic) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer, its treatment.
Drug data last refreshed 13h ago
mu-opioid receptor. When administered at the recommended dose levels, naloxegol functions as a peripherally-acting mu-opioid receptor antagonist in tissues, such as the gastrointestinal tract, thereby decreasing the constipating effects of opioids. Naloxegol is a PEGylated derivative of naloxone…
Worked on NALOXEGOL at Msn Labs Pvt Ltd? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Study on Quality of Life in Advanced Cancer Patients With Opioid-induced Constipation Treated With Naloxegol
Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
The Effect of Naloxegol on Refractory Constipation in the Intensive Care Unit
Naloxegol for the Prevention of Constipation in Postoperative Spinal Surgery Patients
Naloxegol for Opioid-Related Gastroparesis